Outsourced Vaccine Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourced Vaccine Development
The authors discuss how strategic outsourcing to contract manufacturing organizations that have technical and regulatory expertise can add further value during vaccine development.


Pharmaceutical Technology
Volume 33, Issue 7

References

1. Kalorama Information, http://www.kaloramainformation.com/, accessed June 22, 2009.

2. C. Franco, "Billions for Biodefense: Federal Agency Biodefense Funding, FY2008-FY2009," Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, 6 (2), page 131 (2008).

3. PhRMA, "Report on Biotechnology Medicines in Development", 2008, http://www.pharma.org/, accessed June 22, 2009.

4. K.J. Morrow, Jr., "Revamping and Reengineering Existing Technology Can Increase Protein Yield and Efficacy," Gen. Engineer. and Biotechnol. News, 27 (5) 50–54 (2007).

5. Y. Durocher et al., "Scalable serum-free Production of Recombinant adeno-associated Virus Type 2 by Transfection of 293 Suspension cells, Journ. of Virolog. Meth., 144, p. 32 (2007).

6. H.R.G. Clarke, and B.J. Compton, "Comparing Mammalian Expression Systems The First Rate-Limiting Step in Making Products for Clinical Testing," supplement to BioProcess Internat., 6 (11) 24–32 (2008).

7. P. Gagnon, "Monoliths Emerge as Key Purification Methodology," Gen. Engineer. and Biotechnol. News, 28 (14) (2008), http://www.genengnews.com/.

8. C. H. Arnaud, "Analyzing Vaccines," Chem. & Engineer. News, 84 (14), P. 52 (2006).

9. C. Scott, "Formulation Development, Making the Medicine," supplement to BioProcess Internat., 42 (3) 42–56, March 2006.

10. A. Sjolander, J.C. Cox, and I.G. Barr, "ISCOMs: An Adjuvant with Multiple Functions," Jour. of Leukocyte Biol., 64, 713–723 (1998).

11. S. Crossman and J. Lawson, "Considerations for Choosing a CMO," Contract Pharm., 10 (2008), http://www.contractpharma.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here